Healy E, Angus B, Lawrence C M, Rees J L
Department of Dermatology, University of Newcastle upon Tyne, U.K.
Br J Dermatol. 1995 Nov;133(5):737-41. doi: 10.1111/j.1365-2133.1995.tb02748.x.
Recurrence of basal cell carcinoma (BCC) following treatment is a common event and long-term follow-up of all patients presenting with a primary BCC has been recommended. Proliferation indices have been recognized as important prognostic factors in several tumour types in a variety of cancer systems, being significantly elevated in more aggressive lesions. We have examined 51 BCCs (17 non-recurrent tumours [group 1], 17 original tumours which later recurred [group 2-O], and the corresponding 17 recurrent specimens [group 2-R]) for Ki67 antigen expression, a proliferation-associated antigen using immunohistochemistry with the monoclonal antibody MIB1. There was a significant increase in the percentage positive for MIB1 in the Group 2-O as compared with the group 1 BCCs (P < 0.05). p53 protein expression, as assessed by immunohistochemistry with the monoclonal antibody DO7, was similar in each group. These results show that Ki67 antigen expression differs between BCCs which later recur and BCCs that do not recur.
基底细胞癌（BCC）治疗后复发是常见情况，因此建议对所有原发性BCC患者进行长期随访。在多种癌症系统的几种肿瘤类型中，增殖指数已被视为重要的预后因素，在侵袭性更强的病变中显著升高。我们使用单克隆抗体MIB1通过免疫组织化学检查了51例基底细胞癌（17例非复发性肿瘤[第1组]，17例后来复发的原始肿瘤[第2 - O组]，以及相应的17例复发标本[第2 - R组]）中Ki67抗原的表达，Ki67是一种与增殖相关的抗原。与第1组基底细胞癌相比，第2 - O组中MIB1阳性百分比显著增加（P < 0.05）。用单克隆抗体DO7通过免疫组织化学评估的p53蛋白表达在每组中相似。这些结果表明，后来复发的基底细胞癌和未复发的基底细胞癌之间Ki67抗原表达不同。
